<p>Vir Biotechnology, Inc.（纳斯达克代码：VIR - 获取免费报告）在覆盖该公司的十一位分析师中被评定为 “适度买入”，MarketBeat Ratings 报告称。一位研究分析师对该股票给予了卖出建议，一位给予了持有建议，九位给予了买入建议。在过去一年中，对该股票发布评级的经纪公司平均一年目标价为 17.30 美元。</p>
<p>获取 <strong>Vir Biotechnology</strong> 的提醒：</p>
<ul>
<li>从落后者到领军者：小型股正在崛起</li>
</ul>
<p>多位股票分析师对该股票发布了报告。Weiss Ratings 在 12 月 22 日的研究报告中重申了对 Vir Biotechnology 股票的 “卖出（d-）” 评级。Evercore ISI 在 9 月 3 日的研究报告中开始覆盖 Vir Biotechnology，给予了 “跑赢大盘” 的评级和 12.00 美元的目标价。最后，HC Wainwright 在 9 月 15 日的报告中重申了对 Vir Biotechnology 股票的 “买入” 评级，并设定了 15.00 美元的目标价。</p>
<p><strong>阅读我们关于 VIR 的最新报告</strong></p>
<h2>Vir Biotechnology 股票表现</h2>
<ul>
<li>Virios Therapeutics 因纤维肌痛第三阶段提案上涨 75%</li>
</ul>
<p>Vir Biotechnology 股票在周一开盘价为 6.00 美元。Vir Biotechnology 的 52 周低点为 4.16 美元，52 周高点为 14.45 美元。该公司的市值为 8.3472 亿美元，市盈率为-1.66，贝塔值为 1.34。该股票的 50 日移动平均线为 6.00 美元，200 日移动平均线为 5.50 美元。</p>
<p>Vir Biotechnology（纳斯达克代码：VIR - 获取免费报告）最近在 11 月 5 日发布了季度财报。公司报告每股收益（EPS）为（1.17 美元），低于市场共识预期的（0.70 美元）0.47 美元。该公司本季度的收入为 24 万美元，而分析师预期为 198 万美元。Vir Biotechnology 的股本回报率为-50.76%，净利润率为-2963.54%。与去年同期相比，该公司的季度收入增长了 0.8%。去年同期，该公司每股收益为（1.56 美元）。作为一个整体，卖方分析师预测 Vir Biotechnology 在当前财政年度将发布-3.92 美元的每股收益。</p>
<h2>内部买卖</h2>
<p>在相关消息中，首席财务官 Jason O'byrne 在 11 月 17 日的交易中出售了 6799 股公司的股票。股票以平均价格 5.56 美元出售，总价值为 37802.44 美元。交易完成后，首席财务官持有公司 110701 股股票，价值约 615497.56 美元。此次交易使其持股减少了 5.79%。该出售在向 SEC 提交的文件中披露，可以通过此超链接访问。此外，董事 Vicki L. Sato 在 12 月 1 日的交易中出售了 22000 股公司的股票。该股票以平均价格 6.00 美元出售，总交易额为 132000.00 美元。出售后，该董事直接持有公司 1188391 股股票，价值 7130346 美元。这代表其持股减少了 1.82%。该出售的 SEC 文件提供了更多信息。在上个季度，内部人士出售了 3031666 股公司股票，价值 18292045 美元。16.00% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近买卖了该公司的股票。FNY Investment Advisers LLC 在第三季度收购了 Vir Biotechnology 的新股份，价值 38000 美元。Hudson Bay Capital Management LP 在第三季度将其在 Vir Biotechnology 的持股增加了 31.0%。Hudson Bay Capital Management LP 现在拥有 911882 股公司股票，价值 5207000 美元，在此期间又购买了 215882 股。Connective Capital Management LLC 在第三季度购买了 Vir Biotechnology 的新股份，价值约 431000 美元。Sender Co &amp; Partners Inc.在第三季度收购了 Vir Biotechnology 的新股份，价值约 247000 美元。最后，Dark Forest Capital Management LP 在第三季度购买了 Vir Biotechnology 的新股份，价值约 817000 美元。目前 65.32% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Vir Biotechnology</h2>
<p>（获取免费报告）</p>
<p>Vir Biotechnology, Inc 是一家临床阶段的免疫学公司，致力于开发预防和治疗严重传染病的疗法。该公司利用一系列专有技术平台——从抗体分离和筛选工具到基于细胞的检测和生物信息学——来识别和推进抗病毒和抗细菌候选药物。其科学方法集中在通过单克隆抗体和免疫调节剂利用人类免疫系统。</p>
<p>公司的产品管线包括针对流感 A、COVID-19、HIV、乙型肝炎和结核病的候选产品。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好五只股票而非 Vir Biotechnology</li>
<li>请勿删除，立即阅读</li>
<li>富人如何退休</li>
<li>投资者提醒：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
<li>100 万美元在退休后能维持多久？</li>
<li>巴菲特、盖茨和贝索斯悄然抛售股票——原因在这里</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VklS?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VklS"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Vir Biotechnology 吗？</h2>
<p>在考虑 Vir Biotechnology 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Vir Biotechnology 并不在名单上。</p>
<p>虽然 Vir Biotechnology 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Vir Biotechnology, Inc.（纳斯达克代码：VIR）获得了十一位分析师的 “适度买入” 共识评级。平均一年目标价为 17.30 美元，其中九位分析师建议买入，一位建议持有，一位建议卖出。该股票开盘价为 6.00 美元，52 周区间为 4.16 美元至 14.45 美元。公司报告的季度每股收益为（1.17 美元），未达到预期，收入为 24 万美元。内部人士最近出售了大量股份，机构投资者持有 65.32% 的股份。Vir Biotechnology 专注于开发针对严重传染病的疗法</p>

<p>Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has been assigned a consensus rating of &#34;Moderate Buy&#34; from the eleven analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $17.30.</p>
<div class="lb-trans"><p>Vir Biotechnology, Inc.（纳斯达克代码：VIR - 获取免费报告）在覆盖该公司的十一位分析师中被评定为 “适度买入”，MarketBeat Ratings 报告称。一位研究分析师对该股票给予了卖出建议，一位给予了持有建议，九位给予了买入建议。在过去一年中，对该股票发布评级的经纪公司平均一年目标价为 17.30 美元。</p>
</div><p>Get <strong>Vir Biotechnology</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vir Biotechnology</strong> 的提醒：</p>
</div><ul>
<li>From laggards to leaders: Small caps on the rise</li>
</ul>
<div class="lb-trans"><ul>
<li>从落后者到领军者：小型股正在崛起</li>
</ul>
</div><p>A number of equities analysts have issued reports on the stock. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Vir Biotechnology in a research report on Monday, December 22nd. Evercore ISI initiated coverage on Vir Biotechnology in a research note on Wednesday, September 3rd. They issued an &#34;outperform&#34; rating and a $12.00 target price on the stock. Finally, HC Wainwright reiterated a &#34;buy&#34; rating and set a $15.00 target price on shares of Vir Biotechnology in a report on Monday, September 15th.</p>
<div class="lb-trans"><p>多位股票分析师对该股票发布了报告。Weiss Ratings 在 12 月 22 日的研究报告中重申了对 Vir Biotechnology 股票的 “卖出（d-）” 评级。Evercore ISI 在 9 月 3 日的研究报告中开始覆盖 Vir Biotechnology，给予了 “跑赢大盘” 的评级和 12.00 美元的目标价。最后，HC Wainwright 在 9 月 15 日的报告中重申了对 Vir Biotechnology 股票的 “买入” 评级，并设定了 15.00 美元的目标价。</p>
</div><p><strong>Read Our Latest Report on VIR</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 VIR 的最新报告</strong></p>
</div><h2>Vir Biotechnology Stock Performance</h2>
<div class="lb-trans"><h2>Vir Biotechnology 股票表现</h2>
</div><ul>
<li>Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal</li>
</ul>
<div class="lb-trans"><ul>
<li>Virios Therapeutics 因纤维肌痛第三阶段提案上涨 75%</li>
</ul>
</div><p>Vir Biotechnology stock opened at $6.00 on Monday. Vir Biotechnology has a fifty-two week low of $4.16 and a fifty-two week high of $14.45. The firm has a market capitalization of $834.72 million, a price-to-earnings ratio of -1.66 and a beta of 1.34. The stock's fifty day moving average is $6.00 and its two-hundred day moving average is $5.50.</p>
<div class="lb-trans"><p>Vir Biotechnology 股票在周一开盘价为 6.00 美元。Vir Biotechnology 的 52 周低点为 4.16 美元，52 周高点为 14.45 美元。该公司的市值为 8.3472 亿美元，市盈率为-1.66，贝塔值为 1.34。该股票的 50 日移动平均线为 6.00 美元，200 日移动平均线为 5.50 美元。</p>
</div><p>Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.47). The firm had revenue of $0.24 million for the quarter, compared to analyst estimates of $1.98 million. Vir Biotechnology had a negative return on equity of 50.76% and a negative net margin of 2,963.54%.The company's quarterly revenue was up .8% compared to the same quarter last year. During the same period last year, the firm earned ($1.56) EPS. As a group, sell-side analysts forecast that Vir Biotechnology will post -3.92 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Vir Biotechnology（纳斯达克代码：VIR - 获取免费报告）最近在 11 月 5 日发布了季度财报。公司报告每股收益（EPS）为（1.17 美元），低于市场共识预期的（0.70 美元）0.47 美元。该公司本季度的收入为 24 万美元，而分析师预期为 198 万美元。Vir Biotechnology 的股本回报率为-50.76%，净利润率为-2963.54%。与去年同期相比，该公司的季度收入增长了 0.8%。去年同期，该公司每股收益为（1.56 美元）。作为一个整体，卖方分析师预测 Vir Biotechnology 在当前财政年度将发布-3.92 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, CFO Jason O'byrne sold 6,799 shares of the business's stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $5.56, for a total value of $37,802.44. Following the completion of the transaction, the chief financial officer owned 110,701 shares of the company's stock, valued at approximately $615,497.56. The trade was a 5.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 22,000 shares of the firm's stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $6.00, for a total transaction of $132,000.00. Following the sale, the director directly owned 1,188,391 shares in the company, valued at $7,130,346. This represents a 1.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 3,031,666 shares of company stock worth $18,292,045. 16.00% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Jason O'byrne 在 11 月 17 日的交易中出售了 6799 股公司的股票。股票以平均价格 5.56 美元出售，总价值为 37802.44 美元。交易完成后，首席财务官持有公司 110701 股股票，价值约 615497.56 美元。此次交易使其持股减少了 5.79%。该出售在向 SEC 提交的文件中披露，可以通过此超链接访问。此外，董事 Vicki L. Sato 在 12 月 1 日的交易中出售了 22000 股公司的股票。该股票以平均价格 6.00 美元出售，总交易额为 132000.00 美元。出售后，该董事直接持有公司 1188391 股股票，价值 7130346 美元。这代表其持股减少了 1.82%。该出售的 SEC 文件提供了更多信息。在上个季度，内部人士出售了 3031666 股公司股票，价值 18292045 美元。16.00% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently bought and sold shares of the business. FNY Investment Advisers LLC acquired a new stake in shares of Vir Biotechnology during the third quarter worth $38,000. Hudson Bay Capital Management LP lifted its position in Vir Biotechnology by 31.0% during the third quarter. Hudson Bay Capital Management LP now owns 911,882 shares of the company's stock worth $5,207,000 after buying an additional 215,882 shares during the period. Connective Capital Management LLC purchased a new position in Vir Biotechnology during the third quarter worth about $431,000. Sender Co &amp; Partners Inc. acquired a new stake in Vir Biotechnology in the 3rd quarter worth about $247,000. Finally, Dark Forest Capital Management LP purchased a new stake in Vir Biotechnology in the 3rd quarter valued at about $817,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者最近买卖了该公司的股票。FNY Investment Advisers LLC 在第三季度收购了 Vir Biotechnology 的新股份，价值 38000 美元。Hudson Bay Capital Management LP 在第三季度将其在 Vir Biotechnology 的持股增加了 31.0%。Hudson Bay Capital Management LP 现在拥有 911882 股公司股票，价值 5207000 美元，在此期间又购买了 215882 股。Connective Capital Management LLC 在第三季度购买了 Vir Biotechnology 的新股份，价值约 431000 美元。Sender Co &amp; Partners Inc.在第三季度收购了 Vir Biotechnology 的新股份，价值约 247000 美元。最后，Dark Forest Capital Management LP 在第三季度购买了 Vir Biotechnology 的新股份，价值约 817000 美元。目前 65.32% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Vir Biotechnology</h2>
<div class="lb-trans"><h2>关于 Vir Biotechnology</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.</p>
<div class="lb-trans"><p>Vir Biotechnology, Inc 是一家临床阶段的免疫学公司，致力于开发预防和治疗严重传染病的疗法。该公司利用一系列专有技术平台——从抗体分离和筛选工具到基于细胞的检测和生物信息学——来识别和推进抗病毒和抗细菌候选药物。其科学方法集中在通过单克隆抗体和免疫调节剂利用人类免疫系统。</p>
</div><p>The company's pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.</p>
<div class="lb-trans"><p>公司的产品管线包括针对流感 A、COVID-19、HIV、乙型肝炎和结核病的候选产品。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Vir Biotechnology</li>
<li>Do not delete, read immediately</li>
<li>How the Rich Retire</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好五只股票而非 Vir Biotechnology</li>
<li>请勿删除，立即阅读</li>
<li>富人如何退休</li>
<li>投资者提醒：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
<li>100 万美元在退休后能维持多久？</li>
<li>巴菲特、盖茨和贝索斯悄然抛售股票——原因在这里</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VklS" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=VIR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vir Biotechnology Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Vir Biotechnology 吗？</h2>
</div><p>Before you consider Vir Biotechnology, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vir Biotechnology 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vir Biotechnology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Vir Biotechnology 并不在名单上。</p>
</div><p>While Vir Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vir Biotechnology 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Vir Biotechnology, Inc.（纳斯达克代码：VIR）被券商给予 “适度买入” 的平均评级